Coste-efectividad e impacto presupuestario del tratamiento con evolocumab frente a estatinas y ezetimiba para la hipercolesterolemia en España

Lima, Antonio Olry de Labry; Ballester, Vicente Gimeno; Sánchez, Jesús Francisco Sierra; Hoces, Antonio Matas; González-Outón, Julio; Rey, EJ Alegre-Del

doi:10.1016/j.recesp.2018.02.013

Cited by 26 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7 Assuming this scenario in Spain, the yearly cost per patient has been estimated as 872€, 182€ for statins plus ezetimibe, and 5139€ for PCSK9 inhibitors. 8…”

Section: Resultsmentioning

confidence: 99%

“…The calculation was a very simple analysis taking only account the bempedoic acid LDLc reduction and not the real efficacy results. Considering that in previous studies, PCSK9 inhibitors are not cost-effectiveness and they should be reduced the price to meet the cost-efficacy criteria, 8,24 consider substituting PCSK9 inhibitors for bempedoic acid does not seem reasonable. These estimations could be improved and change once the results of the CLEAR OUTCOMES Trial, 22 expected for 2023, would be available.…”

Section: Discussionmentioning

confidence: 99%

“…7 Assuming this scenario in Spain, the yearly cost per patient has been estimated as 872€, 182€ for statins plus ezetimibe, and 5139€ for PCSK9 inhibitors. 8 According to the LDLc reductions (mg/dL) in clinical trials with bempedoic acid, [9][10][11][12][13] and a 1 mmol/L (;39 mg/dL) reduction in LDLc was associated with a 22% reduction in the 5-year incidence of major coronary events. 14 We assume that the reduction in major cardiovascular events over 5 years is constant.…”

Section: Cost-effectivenessmentioning

confidence: 99%

See 2 more Smart Citations

Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness Analysis

Seijas‐Amigo

Cordero

Olmo

et al. 2023

Journal of Cardiovascular Pharmacology

View full text Add to dashboard Cite

show abstract

“…7 Assuming this scenario in Spain, the yearly cost per patient has been estimated as 872€, 182€ for statins plus ezetimibe, and 5139€ for PCSK9 inhibitors. 8…”

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Cost-effectivenessmentioning

confidence: 99%

See 1 more Smart Citation

Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness Analysis

Seijas‐Amigo

Cordero

Olmo

et al. 2023

Journal of Cardiovascular Pharmacology

View full text Add to dashboard Cite

show abstract

“…The CV event is, multifactorial and the effects of the drugs are, in turn, multiple. When establishing common LDL-C objectives based on epidemiological data, all the drugs, and circumstances due to the effects on final clinical variables [51]. Because AD usually precedes the clinical manifestation of the CVD, strategies to treat it focus on pharmacologic intervention.…”

Section: Discussionmentioning

confidence: 99%

Waist Circumference as a Preventive Tool of Atherogenic Dyslipidemia and Obesity-Associated Cardiovascular Risk in Young Adults Males: A Cross-Sectional Pilot Study

et al. 2020

View full text Add to dashboard Cite

Although the correlation coefficient between body mass index (BMI) and poor lipid profile has been reported, representing a cardiovascular risk, the need to find new early detection markers is real. Waist circumference and markers of atherogenic dyslipidemia are not usually measured in medical review appointments. The present study aimed to investigate the relationship between central adiposity and cardiovascular risk. This was a cross-sectional pilot study of 57 young males (age: 35.9 ± 10.85, BMI: 32.4 ± 6.08) recruited from community settings and allocated to non-obese or obese attending to their waist circumference. Total cholesterol (TC), high-density lipoproteins (HDL-C), and low-density lipoproteins (LDL-C) cholesterol and triglycerides (TG) were measured from plasma samples. Patients with at least 100 cm of waist circumference had significantly increased TC, LDL-C, non-HDL-C, and triglycerides and lower levels of HDL-C. The three atherogenic ratios TC/HDL-C, LDL-C/HDL-C, and TG/HDL-C were all optimal in non-obese patients. LDL-C/HDL-C and TG/HDL-C were significantly higher and over the limit when assessing for atherogenic dyslipidemia. The number of patients at risk for cardiovascular events increases 2.5 folds in obese compared to non-obese. Measurement of waist circumference could be adopted as a simpler valid alternative to BMI for health promotion, to alert those at risk of atherogenic dyslipidemia.

show abstract

“…Despite the benefits of evolocumab shown in previous studies, this drug's general use is uncommon due to its relatively high cost compared to statins. 11 Thus, a cost-benefit assessment of treatment with evolocumab should first be considered. 12 As shown in previous studies, the benefit of this treatment depends on the intrinsic characteristics of the population to be treated.…”

Section: Eficacia Del Tratamiento Con Evolocumab En Pacientes Con Cardiopatía Isquémicamentioning

confidence: 99%

Eficacia del tratamiento con evolocumab en pacientes con cardiopatía isquémica

Ramos-Martínez¹,

Mayoral²,

Hernández-Mercado³

et al. 2021

Cardiovasc Metab Sci

View full text Add to dashboard Cite

Se ha establecido un nuevo nivel objetivo de lipoproteína de baja densidad (C-LDL) en pacientes con muy alto riesgo cardiovascular. Sin embargo, no se ha evaluado si el tratamiento con evolocumab en combinación con atorvastatina permite alcanzar estos niveles. Objetivo: Evaluar la eficacia de evolocumab para lograr los niveles objetivo de C-LDL en pacientes con cardiopatía isquémica y muy alto riesgo cardiovascular. Material y métodos: Veinte pacientes con cardiopatía isquémica y muy alto riesgo cardiovascular fueron tratados con evolocumab más atorvastatina durante 24 semanas. Se determinaron los niveles de C-LDL, C-HDL, colesterol total y triglicéridos en suero antes y después del tratamiento. Resultados: Después de las 24 semanas de tratamiento, se obtuvo un promedio del porcentaje de reducción de C-LDL de 55% y 11 de los 20 pacientes alcanzaron los niveles objetivos de C-LDL. No se encontraron diferencias en los niveles de (lipoproteínas de alta densidad) HDL ni de triglicéridos. Conclusiones: El tratamiento con evolocumab fue seguro y eficaz, ya que redujo la concentración de C-LDL en todos los pacientes; sin embargo, sólo se alcanzó el nivel objetivo de C-LDL en la mitad de los pacientes.

show abstract

Coste-efectividad e impacto presupuestario del tratamiento con evolocumab frente a estatinas y ezetimiba para la hipercolesterolemia en España

Cited by 26 publications

References 26 publications

Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness Analysis

Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness Analysis

Waist Circumference as a Preventive Tool of Atherogenic Dyslipidemia and Obesity-Associated Cardiovascular Risk in Young Adults Males: A Cross-Sectional Pilot Study

Eficacia del tratamiento con evolocumab en pacientes con cardiopatía isquémica

Contact Info

Product

Resources

About